Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 19Neuroblastoma 16Leukemia 15Prostatic Neoplasms 14Lymphoma 12Multiple Myeloma 10Breast Neoplasms 10Lymphoma, Non-Hodgkin 8Leukemia, Myeloid, Acute 8Leukemia, Lymphocytic, Chronic, B-Cell 8Glioblastoma 8Neoplasm Metastasis 6Myelodysplastic Syndromes 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Fallopian Tube Neoplasms 6Neoplasms 5Hodgkin Disease 5Carcinoma, Non-Small-Cell Lung 5Uveal Melanoma 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Kidney Neoplasms 4Glioma 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms, Male 4Ovarian Neoplasms 3Neoplasms, Plasma Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3

Interventions

spartalizumab 1Immunotherapy 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Objective Response Rate × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT05760196 2023-03-08

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

Renmin Hospital of Wuhan University

Phase 2 Unknown
56 enrolled

Objective Response Rate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡